Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Diabetic Retinopathy – Pipeline Review, H1 2012

VIEWS: 29 PAGES: 142

Diabetic Retinopathy - Pipeline Review, H1 2012, provides an overview of the Diabetic Retinopathy therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Retinopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy. 'Diabetic Retinopathy - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

More Info
									          Diabetic Retinopathy – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1872IDB
                                                                                             Publication Date: March 2012




Diabetic Retinopathy – Pipeline Review, H1 2012                                             GMDHC1872IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                           Page(1)
Diabetic Retinopathy – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 8
    List of Figures ................................................................................................................................................................................ 9
Introduction....................................................................................................................................................................................... 10
    Global Markets Direct Report Coverage ...................................................................................................................................... 10
Diabetic Retinopathy Overview ........................................................................................................................................................ 11
Therapeutics Development............................................................................................................................................................... 12
    An Overview of Pipeline Products for Diabetic Retinopathy ........................................................................................................ 12
Diabetic Retinopathy Therapeutics under Development by Companies........................................................................................... 14
Diabetic Retinopathy Therapeutics under Investigation by Universities/Institutes ............................................................................ 18
Late Stage Products ......................................................................................................................................................................... 20
    Comparative Analysis .................................................................................................................................................................. 20
Mid Clinical Stage Products.............................................................................................................................................................. 21
    Comparative Analysis .................................................................................................................................................................. 21
Early Clinical Stage Products ........................................................................................................................................................... 22
    Comparative Analysis .................................................................................................................................................................. 22
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 23
    Comparative Analysis .................................................................................................................................................................. 23
Diabetic Retinopathy Therapeutics – Products under Development by Companies......................................................................... 24
Diabetic Retinopathy Therapeutics – Products under Investigation by Universities/Institutes .......................................................... 25
Companies Involved in Diabetic Retinopathy Therapeutics Development ....................................................................................... 26
    Oxford BioMedica plc .................................................................................................................................................................. 26
    Novagali Pharma SA ................................................................................................................................................................... 27
    Vitreoretinal Technologies Inc. .................................................................................................................................................... 28
    VasGene Therapeutics, Inc. ........................................................................................................................................................ 29
    Alchemia Limited ......................................................................................................................................................................... 30
    Evotec Aktiengesellschaft............................................................................................................................................................ 31
    iCo Therapeutics Inc.................................................................................................................................................................... 32
    Antisense Therapeutics Limited................................................................................................................................................... 33
    Lpath, Inc. .................................................................................................................................................................................... 34
    Mesoblast Ltd .............................................................................................................................................................................. 35
    Torrent Pharmaceuticals Limited ................................................................................................................................................. 36
    ThromboGenics NV ..................................................................................................................................................................... 37
    R-Tech Ueno, Ltd. ....................................................................................................................................................................... 38
    Paloma Pharmaceuticals, Inc. ..................................................................................................................................................... 39
    Acucela Inc. ................................................................................................................................................................................. 40
    OcuCure Therapeutics, Inc. ......................................................................................................................................................... 41
    Gene Signal International SA. ..................................................................................................................................................... 42
    Promedior, Inc. ............................................................................................................................................................................ 43
    Akebia Therapeutics, Inc. ............................................................................................................................................................ 44
    DiaKine Therapeutics, Inc. .......................................................................................................................................................... 45
    NOXXON Pharma AG ................................................................................................................................................................. 46



Diabetic Retinopathy – Pipeline Review, H1 2012                                                                                                 GMDHC1872IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Diabetic Retinopathy – Pipeline Review, H1 2012




    Angstrom Pharmaceuticals, Inc. .................................................................................................................................................. 47
    Sirnaomics, Inc. ........................................................................................................................................................................... 48
    Resolvyx Pharmaceuticals, Inc .................................................................................................................................................... 49
    KAI Pharmaceuticals Inc. ............................................................................................................................................................ 50
    TaiGen Biotechnology Co., Ltd. ................................................................................................................................................... 51
    MacuCLEAR, Inc. ........................................................................................................................................................................ 52
    Stelic Institute & Co. .................................................................................................................................................................... 53
    AngioGenex, Inc. ......................................................................................................................................................................... 54
    PanOptica, Inc. ............................................................................................................................................................................ 55
    Cebix Incorporated ...................................................................................................................................................................... 56
    Targa Therapeutics Corp............................................................................................................................................................. 57
    Ampio Pharmaceuticals, Inc. ....................................................................................................................................................... 58
Diabetic Retinopathy – Therapeutics Assessment ........................................................................................................................... 59
    Assessment by Monotherapy Products ....................................................................................................................................... 59
    Assessment by Combination Products ........................................................................................................................................ 60
    Assessment by Route of Administration ...................................................................................................................................... 61
    Assessment by Molecule Type .................................................................................................................................................... 63
Drug Profiles..................................................................................................................................................................................... 66
    ATL1103 - Drug Profile ................................................................................................................................................................ 66
        Product Description................................................................................................................................................................. 66
        Mechanism of Action ............................................................................................................................................................... 66
        R&D Progress ......................................................................................................................................................................... 66
    iCo-007 - Drug Profile .................................................................................................................................................................. 67
        Product Description................................................................................................................................................................. 67
        Mechanism of Action ............................................................................................................................................................... 67
        R&D Progress ......................................................................................................................................................................... 67
    iSONEP - Drug Profile ................................................................................................................................................................. 69
        Product Description................................................................................................................................................................. 69
        Mechanism of Action ............................................................................................................................................................... 69
        R&D Progress ......................................................................................................................................................................... 69
    DG3173 - Drug Profile ................................................................................................................................................................. 71
        Product Description................................................................................................................................................................. 71
        Mechanism of Action ............................................................................................................................................................... 71
        R&D Progress ......................................................................................................................................................................... 71
    VCM For Diabetic Retinopathy - Drug Profile .............................................................................................................................. 72
        Product Description................................................................................................................................................................. 72
        Mechanism of Action ............................................................................................................................................................... 72
        R&D Progress ......................................................................................................................................................................... 72
    Ocriplasmin - Drug Profile ........................................................................................................................................................... 73
        Product Description................................................................................................................................................................. 73
        Mechanism of Action ............................................................................................................................................................... 73
        R&D Progress ......................................................................................................................................................................... 73
    Vitreosolve - Drug Profile ............................................................................................................................................................. 75
        Product Description................................................................................................................................................................. 75


Diabetic Retinopathy – Pipeline Review, H1 2012                                                                                                GMDHC1872IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(3)
Diabetic Retinopathy – Pipeline Review, H1 2012




        Mechanism of Action ............................................................................................................................................................... 75
        R&D Progress ......................................................................................................................................................................... 75
    Cortiject - Drug Profile ................................................................................................................................................................. 76
        Product Description................................................................................................................................................................. 76
        Mechanism of Action ............................................................................................................................................................... 76
        R&D Progress ......................................................................................................................................................................... 76
    DT 23552 - Drug Profile ............................................................................................................................................................... 77
        Product Description................................................................................................................................................................. 77
        Mechanism of Action ............................................................................................................................................................... 77
        R&D Progress ......................................................................................................................................................................... 77
    G Family Inhibitor For Diabetic Retinopathy - Drug Profile .......................................................................................................... 78
        Product Description................................................................................................................................................................. 78
        Mechanism of Action ............................................................................................................................................................... 78
        R&D Progress ......................................................................................................................................................................... 78
    EphB4 Soluble Receptor Program - Drug Profile......................................................................................................................... 79
        Product Description................................................................................................................................................................. 79
        Mechanism of Action ............................................................................................................................................................... 79
        R&D Progress ......................................................................................................................................................................... 79
    Beta PKC Inhibitor Program - Drug Profile .................................................................................................................................. 80
        Product Description................................................................................................................................................................. 80
        Mechanism of Action ............................................................................................................................................................... 80
        R&D Progress ......................................................................................................................................................................... 80
    RX-20001 - Drug Profile .............................................................................................................................................................. 81
        Product Description................................................................................................................................................................. 81
        Mechanism of Action ............................................................................................................................................................... 81
        R&D Progress ......................................................................................................................................................................... 81
    OC-10X - Drug Profile ................................................................................................................................................................. 82
        Product Description................................................................................................................................................................. 82
        Mechanism of Action ............................................................................................................................................................... 82
        R&D Progress ......................................................................................................................................................................... 82
    Granzyme B/VEGF - Drug Profile ................................................................................................................................................ 83
        Product Description................................................................................................................................................................. 83
        Mechanism of Action ............................................................................................................................................................... 83
        R&D Progress ......................................................................................................................................................................... 83
    A6 - Drug Profile .......................................................................................................................................................................... 84
        Product Description................................................................................................................................................................. 84
        Mechanism of Action ............................................................................................................................................................... 84
        R&D Progress ......................................................................................................................................................................... 84
    GS-101 - Drug Profile .................................................................................................................................................................. 85
        Product Description................................................................................................................................................................. 85
        Mechanism of Action ............................................................................................................................................................... 85
        R&D Progress ......................................................................................................................................................................... 85
    Intravitreal/Subconjunctival Palomid 529 - Drug Profile ............................................................................................................... 87
        Product Description................................................................................................................................................................. 87


Diabetic Retinopathy – Pipeline Review, H1 2012                                                                                              GMDHC1872IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                Page(4)
Diabetic Retinopathy – Pipeline Review, H1 2012




        Mechanism of Action ............................................................................................................................................................... 87
        R&D Progress ......................................................................................................................................................................... 87
    Triamcinolone Acetonide - Drug Profile ....................................................................................................................................... 89
        Product Description................................................................................................................................................................. 89
        Mechanism of Action ............................................................................................................................................................... 89
        R&D Progress ......................................................................................................................................................................... 89
    Adalimumab - Drug Profile .......................................................................................................................................................... 90
        Product Description................................................................................................................................................................. 90
        Mechanism of Action
								
To top